Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of nemolizumab in Japanese infants and children with atopic dermatitis and moderate to severe pruritus
jRCT2031230174Phase 3Active, not recruiting
- Sponsor
- Maruho Co., Ltd.
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Nemolizumab with Placebo (2 arms). Started Jun 2023; status: active, not recruiting.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031230174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230174.